Jennifer Huynh1, Grace Xiong, Rhonda Bentley-Lewis. 1. Department of Medicine/Diabetes Unit, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 4-415, Boston, MA, 02114, USA.
Abstract
AIMS/HYPOTHESIS: Gestational diabetes mellitus is associated with adverse maternal and fetal outcomes during, as well as subsequent to, pregnancy, including increased risk of type 2 diabetes and cardiovascular disease. Because of the importance of early risk stratification in preventing these complications, improved first-trimester biomarker determination for diagnosing gestational diabetes would enhance our ability to optimise both maternal and fetal health. Metabolomic profiling, the systematic study of small molecule products of biochemical pathways, has shown promise in the identification of key metabolites associated with the pathogenesis of several metabolic diseases, including gestational diabetes. This article provides a systematic review of the current state of research on biomarkers and gestational diabetes and discusses the clinical relevance of metabolomics in the prediction, diagnosis and management of gestational diabetes. METHODS: We conducted a systematic search of MEDLINE (PubMed) up to the end of February 2014 using the key term combinations of 'metabolomics,' 'metabonomics,' 'nuclear magnetic spectroscopy,' 'mass spectrometry,' 'metabolic profiling' and 'amino acid profile' combined (AND) with 'gestational diabetes'. Additional articles were identified through searching the reference lists from included studies. Quality assessment of included articles was conducted through the use of QUADOMICS. RESULTS: This systematic review included 17 articles. The biomarkers most consistently associated with gestational diabetes were asymmetric dimethylarginine and NEFAs. After QUADOMICS analysis, 13 of the 17 included studies were classified as 'high quality'. CONCLUSIONS/ INTERPRETATION: Existing metabolomic studies of gestational diabetes present inconsistent findings regarding metabolite profile characteristics. Further studies are needed in larger, more racially/ethnically diverse populations.
AIMS/HYPOTHESIS: Gestational diabetes mellitus is associated with adverse maternal and fetal outcomes during, as well as subsequent to, pregnancy, including increased risk of type 2 diabetes and cardiovascular disease. Because of the importance of early risk stratification in preventing these complications, improved first-trimester biomarker determination for diagnosing gestational diabetes would enhance our ability to optimise both maternal and fetal health. Metabolomic profiling, the systematic study of small molecule products of biochemical pathways, has shown promise in the identification of key metabolites associated with the pathogenesis of several metabolic diseases, including gestational diabetes. This article provides a systematic review of the current state of research on biomarkers and gestational diabetes and discusses the clinical relevance of metabolomics in the prediction, diagnosis and management of gestational diabetes. METHODS: We conducted a systematic search of MEDLINE (PubMed) up to the end of February 2014 using the key term combinations of 'metabolomics,' 'metabonomics,' 'nuclear magnetic spectroscopy,' 'mass spectrometry,' 'metabolic profiling' and 'amino acid profile' combined (AND) with 'gestational diabetes'. Additional articles were identified through searching the reference lists from included studies. Quality assessment of included articles was conducted through the use of QUADOMICS. RESULTS: This systematic review included 17 articles. The biomarkers most consistently associated with gestational diabetes were asymmetric dimethylarginine and NEFAs. After QUADOMICS analysis, 13 of the 17 included studies were classified as 'high quality'. CONCLUSIONS/ INTERPRETATION: Existing metabolomic studies of gestational diabetes present inconsistent findings regarding metabolite profile characteristics. Further studies are needed in larger, more racially/ethnically diverse populations.
Authors: R H Böger; S M Bode-Böger; A Szuba; P S Tsao; J R Chan; O Tangphao; T F Blaschke; J P Cooke Journal: Circulation Date: 1998-11-03 Impact factor: 29.690
Authors: Ravi Thadhani; Camille E Powe; May Lee Tjoa; Eliyahu Khankin; Jun Ye; Jeffrey Ecker; Alan Schneyer; S Ananth Karumanchi Journal: Diabetes Care Date: 2009-12-10 Impact factor: 19.112
Authors: Jennifer E Ho; Martin G Larson; Ramachandran S Vasan; Anahita Ghorbani; Susan Cheng; Eugene P Rhee; Jose C Florez; Clary B Clish; Robert E Gerszten; Thomas J Wang Journal: Diabetes Date: 2013-02-04 Impact factor: 9.461
Authors: Victoria Sandler; Anna C Reisetter; James R Bain; Michael J Muehlbauer; Michael Nodzenski; Robert D Stevens; Olga Ilkayeva; Lynn P Lowe; Boyd E Metzger; Christopher B Newgard; Denise M Scholtens; William L Lowe Journal: Diabetologia Date: 2016-12-16 Impact factor: 10.122
Authors: Rhonda Bentley-Lewis; Jennifer Huynh; Grace Xiong; Hang Lee; Julia Wenger; Clary Clish; David Nathan; Ravi Thadhani; Robert Gerszten Journal: Diabetologia Date: 2015-03-07 Impact factor: 10.122
Authors: Fieke Terstappen; Angela J C Tol; Hendrik Gremmels; Kimberley E Wever; Nina D Paauw; Jaap A Joles; Eline M van der Beek; A Titia Lely Journal: Nutrients Date: 2020-08-21 Impact factor: 5.717
Authors: Emanuelly Bernardes-Oliveira; Daniel Lucas Dantas de Freitas; Camilo de Lelis Medeiros de Morais; Maria da Conceição de Mesquita Cornetta; Juliana Dantas de Araújo Santos Camargo; Kassio Michell Gomes de Lima; Janaina Cristiana de Oliveira Crispim Journal: Sci Rep Date: 2020-11-06 Impact factor: 4.379